Vest Financial LLC Acquires 2,178 Shares of Eli Lilly and Company $LLY

Vest Financial LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 23.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,328 shares of the company’s stock after purchasing an additional 2,178 shares during the period. Vest Financial LLC’s holdings in Eli Lilly and Company were worth $8,643,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $29,000. Steph & Co. lifted its holdings in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company in the second quarter valued at $31,000. Finally, Bare Financial Services Inc increased its stake in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s ovarian cancer candidate sofetabart (mipitecan), boosting the company’s oncology outlook and potential near-term regulatory value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: SURMOUNT-REAL UK phase 4 update supports real‑world evidence for tirzepatide’s obesity benefit, which helps validate long-term market adoption and pricing power for Lilly’s GLP-1/dual-agonist franchise. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Retatrutide trial shows potential knee osteoarthritis relief tied to obesity treatment, suggesting additional indications and expanded patient populations for Lilly’s obesity pipeline. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: Lilly launches a Phase 2 trial for a new oral drug targeting diabetic nerve pain, expanding non-GLP-1 growth avenues and diversifying future revenue streams. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Lilly confirmed its Q4 2025 results and investor call for Feb. 4, giving the market a near-term event to reset guidance and expectations. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Analysts at Guggenheim trimmed LLY’s price target marginally (from $1,163 to $1,161) but kept a buy rating—little change to consensus upside but worth noting as analyst attention remains high. LLY: price target lowered by Guggenheim
• Neutral Sentiment: Market pieces and retrospectives highlight strong historical returns and positive analyst narratives (e.g., MarketBeat, Benzinga), supporting investor confidence but not constituting new catalysts. Here’s How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
• Negative Sentiment: Commentary on Novo Nordisk’s new CEO and competitive strategy raises the profile of intense GLP-1 rivalry; investors may be watching pricing, market share, and promotional dynamics between LLY and Novo. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Eli Lilly and Company Stock Up 3.6%

Shares of NYSE LLY opened at $1,078.98 on Thursday. The firm has a fifty day simple moving average of $1,055.07 and a two-hundred day simple moving average of $876.57. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $1.02 trillion, a PE ratio of 52.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on LLY shares. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Bank of America cut their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Finally, Zacks Research upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.